Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05721222

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

Phase 1/2 Study of PRO1160 in Patients With Metastatic Renal Cell Carcinoma (RCC), Metastatic or Relapsed Nasopharyngeal Carcinoma (NPC), or Advanced (Stage III or IV) Non-Hodgkin Lymphoma (NHL)

Sponsor: Genmab

Conditions Nasopharyngeal Carcinoma Non Hodgkin Lymphoma Renal Cell Carcinoma

Interventions GEN1160

Updated 18 times since 2023 Last updated: Mar 2, 2026 Started: Mar 15, 2023 Primary completion: Nov 5, 2025 Completion: Nov 5, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment

Other terminated trials from Genmab

See all terminations from Genmab

Other Nasopharyngeal Carcinoma trials with similar outcome

Browse all Nasopharyngeal Carcinoma trials

This PHASE1/PHASE2 trial investigates Nasopharyngeal Carcinoma and Non Hodgkin Lymphoma and is currently terminated or withdrawn. Genmab leads this study, which shows 18 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

18 versions recorded

Mar 2026 — Present [monthly]

Terminated PHASE1/PHASE2
Dec 2025 — Mar 2026 [monthly]

Terminated PHASE1/PHASE2

Status: Recruiting → Terminated
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 13 earlier versions

Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genmab

Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Beijing, China , Charlotte, United States , Cleveland, United States , Detroit, United States , Duarte, United States , Houston, United States , Irvine, United States , Nashville, United States , New York, United States and 5 more locations